Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

234
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
234
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
245

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Patient Safety Incidents Involving Sick Children in Primary Care in England and Wales: A Mixed Methods Analysis.

PLoS medicine·2017
Same author

Acid-suppressive medications during pregnancy and risk of asthma and allergy in children: A systematic review and meta-analysis.

The Journal of allergy and clinical immunology·2017
Same author

Establishing data-intensive healthcare: the case of Hospital Electronic Prescribing and Medicines Administration systems in Scotland.

Journal of innovation in health informatics·2017
Same author

Tightrope walking towards maximising secondary uses of digitised health data: a qualitative study.

Journal of innovation in health informatics·2017
Same author

A systematic scoping review of the domains and innovations in secondary uses of digitised health-related data.

Journal of innovation in health informatics·2017
Same author

Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5-12 years.

NPJ primary care respiratory medicine·2017

相关实验视频

Updated: Jun 7, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

抗糖尿病药物和喘发作 抗糖尿病药物和喘发作

Bohee Lee1, Kenneth K C Man2, Ernie Wong1

  • 1National Heart and Lung Institute, Imperial College London, London, England.

JAMA internal medicine
|November 18, 2024
PubMed
概括
此摘要是机器生成的。

在患有喘的2型糖尿病患者中使用甲胺与较少的喘发作有关. 添加类似葡萄糖类-1受体激动剂 (GLP-1RA) 进一步减少了喘恶化,独立于血糖控制或体重.

更多相关视频

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

5.9K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

相关实验视频

Last Updated: Jun 7, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

5.9K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

科学领域:

  • 呼吸系统医学 呼吸系统医学
  • 内分泌学 在内分泌学.
  • 临床流行病学临床流行病学

背景情况:

  • 在喘患者中,增加的BMI和2型糖尿病很常见,增加了喘发作风险.
  • 实验研究表明,甲福明和GLP-1RA可以减少气道炎症和高反应性.
  • 关于这些糖尿病药物对喘恶化影响的流行病学数据有限.

研究的目的:

  • 评估甲福明和补充抗糖尿病药物与喘发作之间的关联.
  • 调查GLP-1RA,DPP-4抑制剂,硫尿素,SGLT2抑制剂和胰岛素的作用.
  • 探索代谢/喘表型与药物效应之间的相互作用.

主要方法:

  • 利用英国CPRD Aurum数据 (2004-2020年) 与相关的住院病例.
  • 采用自控病例系列 (SCCS) 和甲胺新用户队列 (IPTW) 进行 robust 分析.
  • 主要结局:第一个喘恶化在12个月内;次要:补充药物效应.

主要成果:

  • 在SCCS (IRR 0.68) 和IPTW (HR 0.76) 分析中,甲胺与喘发作率的降低有关.
  • GLP-1RA显示了一个附加的关联与进一步减少喘发作 (SCCS IRR 0.60).
  • 在负对照分析中没有发现显著偏差;影响独立于BMI,血糖控制或喘严重程度.

结论:

  • 甲胺使用与2型糖尿病患者中喘发作发生率较低有关.
  • GLP-1RA在减少喘发作方面显示出一种附加的益处.
  • 这些好处似乎通过超出血糖控制或减肥的机制在各种喘表型中发挥作用.